Eledon Pharmaceuticals, Inc. announced on February 7, 2025, that its investigational anti-CD40L antibody, tegoprubart, was a key component of the immunosuppression regimen in a patient who received a genetically modified pig kidney transplant. The procedure was performed on January 25, 2025, at Massachusetts General Hospital in collaboration with eGenesis.
Following the successful transplant, the patient was discharged from the hospital and is now off dialysis for the first time in over two years. The FDA had approved this transplant in December 2024, with plans for two additional xenotransplants this year.
Tegoprubart's role in this landmark procedure underscores its potential to improve safety and efficacy in transplantation by blocking CD40L, a critical component of immune cell communication. This marks the second time tegoprubart has been used in a xenotransplant, following its use in a pig heart transplant in September 2023.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.